Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory.
作者信息
Simner Patricia J, Palavecino Elizabeth L, Satlin Michael J, Mathers Amy J, Weinstein Melvin P, Lewis James S, Humphries Romney
机构信息
Department of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
J Clin Microbiol. 2023 Apr 20;61(4):e0160022. doi: 10.1128/jcm.01600-22. Epub 2023 Mar 22.
Abstract
摘要
相似文献
1
Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory.头孢地尔药敏结果不准确的可能性：CLSI抗菌药物敏感性试验分委员会的建议
J Clin Microbiol. 2023 Apr 20;61(4):e0160022. doi: 10.1128/jcm.01600-22. Epub 2023 Mar 22.
2
In-vitro approaches for cefiderocol susceptibility testing and interpretation in the context of recent Clinical & Laboratory Standards Institute advisory.
Indian J Med Microbiol. 2024 Jul-Aug;50:100622. doi: 10.1016/j.ijmmb.2024.100622. Epub 2024 Jun 4.
3
Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.头孢地尔对多重耐药革兰氏阴性杆菌的药敏试验：纸片扩散法与肉汤微量稀释法的比较
J Clin Microbiol. 2020 Dec 17;59(1). doi: 10.1128/JCM.01649-20.
4
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?头孢地尔抗菌药物敏感性试验的考量：特洛伊木马的阿喀琉斯之踵？
J Clin Microbiol. 2020 Dec 17;59(1). doi: 10.1128/JCM.00951-20.
5
Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller-Hinton Agar.评估使用不同品牌 Mueller-Hinton 琼脂对头孢地尔进行纸片扩散试验解释的变异性。
J Appl Lab Med. 2023 May 4;8(3):523-534. doi: 10.1093/jalm/jfac131.
6
Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan.台湾临床微生物实验室针对肠杆菌科细菌遵循临床和实验室标准协会（CLSI）抗菌药物敏感性试验指南（CLSI - 2010及CLSI - 2010更新版）的共识声明。
J Microbiol Immunol Infect. 2010 Oct;43(5):452-5. doi: 10.1016/S1684-1182(10)60070-9.
7
Higher rates of cefiderocol resistance among NDM producing bloodstream isolates applying EUCAST over CLSI breakpoints.应用 EUCAST 折点标准而非 CLSI 折点标准时，产 NDM 血流分离株的头孢地尔耐药率更高。
Infect Dis (Lond). 2023 Sep;55(9):607-613. doi: 10.1080/23744235.2023.2226709. Epub 2023 Jun 30.
8
Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.制定抗菌药物敏感性测试折点：临床和实验室标准研究所方法简介，供儿科传染病专家使用。
J Pediatric Infect Dis Soc. 2022 Feb 23;11(2):73-80. doi: 10.1093/jpids/piab106.
9
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic.铜绿假单胞菌对头孢地尔罗耐药性的演变：一位既往未使用过该抗生素患者的病例报告。
Clin Infect Dis. 2021 Dec 6;73(11):e4472-e4474. doi: 10.1093/cid/ciaa1909.
10
Comparison of cefiderocol in-vitro susceptibility testing modalities.头孢地尔体外药敏试验方法的比较。
J Glob Antimicrob Resist. 2024 Jun;37:100-101. doi: 10.1016/j.jgar.2024.03.011. Epub 2024 Mar 27.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.评价头孢地尔的抗菌药物敏感性试验方法：对当前实践和未来方向的综述与专家意见
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method.市售培养基对头孢地尔肉汤微量稀释法药敏试验的影响。
J Clin Microbiol. 2025 Sep 10;63(9):e0047125. doi: 10.1128/jcm.00471-25. Epub 2025 Aug 20.
3
Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions.《临床和实验室标准协会抗菌药物敏感性试验性能标准的变化概述：M100第32版和第33版》
J Clin Microbiol. 2025 Sep 10;63(9):e0162323. doi: 10.1128/jcm.01623-23. Epub 2025 Aug 7.
4
Impact of media brand on cefiderocol disk diffusion results.媒体品牌对头孢地尔纸片扩散结果的影响。
J Clin Microbiol. 2025 May 14;63(5):e0164824. doi: 10.1128/jcm.01648-24. Epub 2025 Mar 25.
5
Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report.研究性抗生素头孢吡肟/齐德巴坦作为治疗一名由广泛耐药铜绿假单胞菌引起的小儿难治性脓胸的治疗选择：病例报告
Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1349-1355. doi: 10.1007/s10096-025-05106-8. Epub 2025 Mar 18.
6
A multicenter performance evaluation of cefiderocol MIC results: ComASP in comparison to CLSI broth microdilution.头孢地尔最低抑菌浓度（MIC）结果的多中心性能评估：与临床和实验室标准协会（CLSI）肉汤微量稀释法相比的ComASP法
J Clin Microbiol. 2025 Feb 19;63(2):e0092624. doi: 10.1128/jcm.00926-24. Epub 2024 Dec 31.
7
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
8
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?英国一个大型中心产碳青霉烯酶肠杆菌科细菌的耐药谱：我们是否已经在失去头孢地尔？
J Antimicrob Chemother. 2025 Jan 3;80(1):59-67. doi: 10.1093/jac/dkae367.
9
The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review.治疗产金属β-内酰胺酶革兰氏阴性菌引起的感染面临的挑战：一篇叙述性综述
Drugs. 2024 Dec;84(12):1519-1539. doi: 10.1007/s40265-024-02102-8. Epub 2024 Oct 28.
10
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant infections.接受头孢地尔治疗碳青霉烯耐药感染患者中头孢地尔异质性耐药的发生率。
JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct.
本文引用的文献
1
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?头孢地尔抗菌药物敏感性试验的考量：特洛伊木马的阿喀琉斯之踵？
J Clin Microbiol. 2020 Dec 17;59(1). doi: 10.1128/JCM.00951-20.
2
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.头孢地尔罗酯对广泛临床重要革兰氏阴性菌的体外活性。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551. doi: 10.1093/cid/ciz827.
3
The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics.铁和铁载体在感染中的作用，以及铁载体抗生素的发展。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S529-S537. doi: 10.1093/cid/ciz825.
4
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
Zotero 插件